4th Quarter - Report

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

Firm
Client
Income
—
Expenses
$120,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Health care reform implementation, generally; Food and Drug Administration Safety and Innovation Act (PL 112-144) implementation; sequestration; drug shortages; DEA quotas for controlled substances; ADHD medication; exclusivity periods; fast track and accelerated approvals; priority vouchers; end stage renal disease Prospective Payment System (ESRD PPS); drug importation; orphan drugs; drug compounding; drug innovation and patient access; H.R. 2672, Preserving Access to Orphan Drugs Act of 2011, annual fees on orphan drugs; S. 1423, Preserving Access to Orphan Drugs Act of 2011, annual fees on orphan drugs; H.R. 8, American Taxpayer Relief Act of 2012, orphan drug tax credit; S. 481, the Federal Response to Eliminate Eating Disorders Act

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2672 (112th), S. 1423 (112th), H.R. 8 (112th), S. 481 (112th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.